JSW
CORT icon

Journey Strategic Wealth’s Corcept Therapeutics CORT Stock Holding History

Journey Strategic Wealth’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,538
Closed -$211K – 779
2025
Q3 		$211K Sell
2,538
-252
-9% -$18.2K 0.01% 645
2025
Q2 		$205K Buy
2,790
+856
+44% +$62.1K 0.01% 613
2025
Q1 		$221K Buy
+1,934
New +$118K 0.01% 440

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Journey Strategic Wealth's CORT Position: Q4 2025 in Review

Journey Strategic Wealth sold out of Corcept Therapeutics (CORT) in Q4 2025, closing a stake of 2,538 shares — an estimated $211K sold.

Journey Strategic Wealth first reported a position in CORT in Q1 2025 and held it in 3 quarters. The position peaked at $221K in Q1 2025. 389 funds tracked by Wall St. Rank hold CORT as of Q4 2025.

  • Journey Strategic Wealth reported no remaining Corcept Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Journey Strategic Wealth sold 2,538 Corcept Therapeutics shares in Q4 2025, an estimated $211K.
  • Journey Strategic Wealth first reported a position in Corcept Therapeutics in Q1 2025 and held it in 3 quarters.
  • Journey Strategic Wealth's Corcept Therapeutics position peaked at $221K in Q1 2025.
  • 389 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2025.

Based on Journey Strategic Wealth's 13F filing for Q4 2025, filed 13 Feb 2026.